SEC Filing Summary: Hemispherx Biopharma, Inc.
Business Context and Reporting Period
This Form 8-K Current Report was filed by Hemispherx Biopharma, Inc. on July 15, 2004, regarding events that occurred on July 13, 2004. The filing discloses the exercise of various warrants and investment rights by security holders.
Key Financial Metrics and Transactions
The company received gross proceeds of $4,198,980 from the exercise of the following securities:
- Warrants issued in October 2003 for 410,134 shares at an exercise price of $2.32 per share.
- Warrants issued in July 2003 for 507,102 shares at an exercise price of $2.46 per share.
- Additional investment rights issued in January 2004 for $2,000,000 in principal amount of 6% senior secured convertible debentures due January 31, 2006.
In connection with these exercises, the company issued new warrants (the "June 2009 Warrants") to purchase an aggregate of 1,300,000 shares of common stock. These warrants have an initial exercise price of $3.75 per share and are exercisable from January 13, 2005, through June 30, 2009.
Material Changes
The primary material change is the increase in cash proceeds of approximately $4.2 million and the issuance of 1,300,000 new warrants, which represents potential future dilution. The filing does not provide comparative financial data for prior periods or specific changes to revenue, profit, or margins.
Outlook, Risks, and Contingencies
The company has agreed to register the shares issuable upon exercise of the June 2009 Warrants under terms substantially similar to the Registration Rights Agreement dated January 26, 2004, with modifications as set forth in the Form of Warrant (Exhibit 10.1). The filing does not contain specific management commentary on future business outlook, risks, or unusual items beyond the transaction details.
Investor Verification Checklist
- Verify the impact of the $4,198,980 cash inflow on the company's liquidity position.
- Review the dilution effect of the 1,300,000 new warrants exercisable at $3.75 per share.
- Confirm the terms of the 6% senior secured convertible debentures due January 31, 2006.
- Examine Exhibit 10.1 for the specific terms of the June 2009 Warrants and the modified Registration Rights Agreement.